Plant-Based Diets and Disease Progression in Men With Prostate Cancer _
Authors: Vivian N. Liu, MAS; Erin L. Van Blarigan, ScD; Li Zhang, PhD; Rebecca E. Graff, ScD; Stacy Loeb, MD; Crystal S. Langlais, PhD; Janet E. Cowan, MA; Peter R. Carroll, MD, MPH; June M. Chan, ScD; Stacey A. Kenfield, ScD This article examines whether...
Early diagnosis is key to surviving prostate cancer
Dr. Gregory Merrick says the key to surviving prostate cancer is to undergo screening for early prostate cancer detection. That combined with a healthy lifestyle is key to men's health. You can read his whole interview here: "Early Diagnosis Remains Key to Surviving...
September is Prostate Cancer Awareness Month!
September is National Prostate Cancer Awareness Month. Did you know that one in six men will be diagnosed with prostate cancer during their lifetime. It's important to talk to your family and friends about the risk of prostate cancer, and the importance of screening....
Finland study finds how genetic mutation can cause aggressive forms of prostate cancer
Researchers at the University of Oulu in Finland, have found that a type of mutation in a single nucleotide plays a role in the development of aggressive prostate cancer. The study identified several key risk factors involved, and genetic predisposition was one of the...
Study finds nearly 3 out of 4 men on active surveillance are failing to get appropriate follow-up
The second most common cancer in men worldwide (after skin cancer) is still prostate cancer. Most cases diagnosed are slow growing, and may not require immediate treatment. Therefore, a lot of patients pursue active surveillance. According to a recent study in...
Check out the latest video from PCaFree Foundation
Click here to view our latest video featuring Dr. Alex Hsi.
More and more men with low-risk prostate cancer are pursuing active surveillance over aggressive treatment.
More American men with low-risk prostate cancer are being persuaded by their doctor to reject immediate surgery and/or radiation in favor of active surveillance. This move is sparing men’s sexual health without increasing their risk of death. A study done by the VA...
New Prostate Cancer Prognostic Test Soon-To-Be Available
A new prostate cancer prognostic test is in the works and soon-to-be available worldwide. MDxHealth recently signed an agreement that gives it licensing rights to market and manufacture the test. The test, InformMDx, looks at the recently validated biomarker PDE4D7,...
Prostate Cancer isn’t Just a “Man’s Disease”
It’s a simple fact anatomical fact that women will never have to worry about receiving their own prostate cancer diagnosis. Prostate cancer has long been referred to as a “man’s disease,” one must not overlook the burden that is shared by the patient’s partner. A...
New Support Program for Prostate Cancer Survivors in the UK helps ease psychological stress
Researchers at the University of Surrey and National Health Service in the U.K. have developed a web-based online cognitive behavioral therapy sessions and both filmed and interactive peer support. Every year, over 47,000 men are diagnosed with prostate cancer in...
Before you can treat prostate cancer, its important to treat fear first
For many people, the words, “you have cancer” are synonymous with a death sentence. Many people start to think of all the people they knew who died within a year of their diagnosis. Within this fear, people tend to think they need the most extreme/aggressive...
SpaceOAR Hydrogel Now Covered by Medicare
As of January 1, 2018, a new technology called SpaceOAR™ Hydrogel is now a covered procedure by Medicare. This product protects the rectum from unintended damage during radiation therapy for prostate cancer. SpaceOAR™ is a gel that is placed through a needle in...
Better Way to Screen for Drug-resistant Prostate Cancer?
Researchers at the University of Toronto may have found a better way to identify prostate cancer patients who may not respond to first-line treatments. Tumors that are drug-resistant, have circulating tumor cells that often times have high levels of particular...
Another Tool in the Treatment of Recurrent Prostate Cancer
A recent article published in the New England Journal of Medicine reports a study showing the benefit of a new hormonal medication in reducing the development of prostate cancer metastases. About 1200 men from 26 countries throughout the world were enrolled in the...
Qualifying for Social Security Disability With Prostate Cancer
The information below was provided by Disability Benefits Help. We hope our viewers in the United States will find it helpful. Men who have been diagnosed with prostate cancer might qualify for Social Security disability benefits....
New Study finds Single High Dose Rate Brachytherapy is Effective against Prostate Cancer
New research shows that a single high-dose brachytherapy treatment is as effective and safe against localized prostate cancer as many low dose over time. The researchers at Oakland University’s William Beaumont School of Medicine in Royal Oaks, Michigan, said “It is...
PCa Commentary #121: AR-V7: The Clinical Utility of Knowing Your Status … And When Is the Information Most Useful.
A test for the splice-variant AR-V7, Oncotype Dx AR-V7 Nucleus Detect (Genomic Health, Inc.), has become commercially available. This Commentary will focus on the clinical significance of test results — their predictive and prognostic value. The Major Foundation...
When it comes to your health, you are your best advocate.
The PSA blood test…sounds harmless enough, and not that hard to do; and yet, according to a 2016 study published in JAMA International Medicine found that PSA (prostate specific antigen) testing- a blood test used to screen for prostate cancer- is on the decline. The...
Can Exercise Improve Prostate Cancer Patients’ Survival?-Global Study to find out
The study is called the Global Action Plan 4 Global Prostate Cancer (GAP4), and will include more than 150 researchers from around the world. The clinical trial will be looking to see if exercise can improve cancer symptoms and delay the disease’s progression. The...
Big Dangers when it comes to Pain management
When it comes to “pain management”, most people automatically think of over the counter medications. They take the prescribed dose, the medication goes to work, and the pain is managed; often times it is short-lived, and they can move on from it. But, for many...
Actor Stephen Fry reveals he has prostate cancer
Last week, Actor Stephen Fry revealed that for the past few months, he has been battling prostate cancer. Fry credits early detection: "I felt my life was saved by early intervention so I would urge any of you men of a certain age to get your PSA levels checked." ...
PCa Commentary
Expert Commentary On The Latest Prostate Cancer Topics
Written by Dr. Ed Weber
PCa Commentary is a well-researched, clearly presented commentary targeted to medical providers and others interested in current prostate cancer treatment. Each PCa Commentary edition offers an analysis of new developments in the field of prostate cancer with essays discussing and evaluating treatment management options for this disease.
PCa Commentary #205 – The Venerable PSA: It Lacks Specificity for Distinguishing Significant Cancer, Which Is Better Addressed by Urine Genomics.
Background: In 1970 the antigen, PSA, was found in semen and prostate tissue. In 1980, it entered clinical service to guide biopsies for suspected cancer and monitor prostate cancer treatment. Before this, prostate cancer was diagnosed, often at a late stage, by...
PCa Commentary # 204 – Management of Transformed Neuroendocrine Prostate Cancer “tNEPC” — An Unmet Challenge.
Background: Neuroendocrine cells are normal constituents of the prostate. They perform a regulatory role influencing growth and differentiation. Spread throughout the body, they receive signals from the nervous system to secrete hormones that govern other systems. ...
PCa Commentary #203 – A PRIMER: PROTACs (Proteolysis Targeting Chimeras) – Drugs That Specifically Target the Androgen Receptor for Destruction.
Prologue: The first issue of the PCa Commentary, October 1, 2002, featured the pivotal importance of the androgen receptor in all phases of prostate cancer … and the androgen receptor’s significance continues today. Background: Research in 1941 by the physiologist...
PCa Commentary # 202 – FDA approves [177Lu]-PSMA-617 for Early Use Based on the PSMAfore Clinical Trial; and 225-Actinium Radioligand Therapies Under Development for Metastatic Castration-Resistant Prostate Cancer
The PSMAfore protocol was FDA approved on March 28, 2025, moving the option of using [177Lu]-PSMA-617 front-forward in early progressive metastatic castration-resistant prostate cancer (mCRPC). Currently, metastatic castration-resistant PC is treated with...
PCa Commentary #201 – Update of the Patch Trial and Information About transdermal Estradiol Usage.
Brief Review of Findings in the Original Langley Abstract Presented at Eur Soc Med Oncol, Sept. 2024: The PATCH Trial established that transdermal estradiol (tE2) patches were equally effective as Lupron in achieving metastasis-free and overall survival in newly...
PCa Commentary #200 – Focal Therapy of Prostate Cancer – An Emerging Technique for Initial Treatment of Localized Disease
With the increasing accuracy of imaging to define the volume and boundary of a solitary lesion, interest and research in focal ablation have increased. The outcomes of multiple techniques have been reported: high-frequency ultrasound, cryoablation, brachytherapy,...
PCa Commentary #199 – Prostate-directed Therapy in Oligo-Metastatic Hormone-Sensitive Prostate Cancer (omHSPC) – The New Paradigm
A consensus has emerged that in mHSPC prostate-directed therapy improves overall survival. This treatment is appropriate in the 20% - 30% of men with high-risk or locally advanced cancer (Gleason Score 8 - 10, PSA >20 ng/mL and local spread around the gland) who,...
PCa Commentary #198 – “Pluvicto” (177Lutetium-PSMA-617) Therapy for Prostate Cancer – What’s Coming up in the Future for Pluvicto? Updated Results, Patient Selection Guidance, Early Use and 177Lu in Combination.
Pluvicto was approved in March 2022 for therapy in men with heavily pretreated castration resistant metastatic prostate cancer, and since, it has become a frequently prescribed life-prolonging treatment. As reported by Sartor et al., NEJM 2021 the median...
PCa Commentary #197 – ANDROGEN DEPRIVATION THERAPY (ADT) – When – early or delayed, – and how.
After primary therapy about 30% of men who are at high risk for recurrence experience disease progression — indicated by a PSA rising above their post-treatment baseline value. These are men whose initial PSA was above ~20 ng/mL with Gleason scores of 4+3 or higher...
PCa Commentary #196 – “My Prostate Test”: A Risk Stratification Model for Outcome Post Prostatectomy: Eligibility for Active Surveillance ; and Relative Benefit of Short’Term ADT Added to Radiation Therapy – all combined in the “ArteraAI Prostate Test”
When based on extensive data sets composed of fully defined characteristics of the patients likely to utilize the model, AI can make an accurate prediction of outcome for an individual patient. These requirements were met by Spratt et al. in developing the first...
Remission versus Recurrence?
Relapse of prostate cancer is way more common than you might think. Many men treated for prostate cancer have their cancer return, which can lead to a lifetime of treatment. Prostate Cancer Free studies treatment outcomes documented in "The STUDY", recently updated for 2021. Take this Study to your doctor, and discuss your chance of cancer recurrence. The Study is available with the new, just released booklet, to help you learn about prostate cancer. Both the Prostate Cancer Free Study and the booklet, “What You Need to Know About Prostate Cancer” are available NOW for you to VIEW, PRINT or DOWNLOAD.
Help To Continue the Work!
The Prostate Cancer Free Foundation, reviews the results of hundreds of thousands of men treated for prostate cancer. Tracking them for years. This information is available to you, and others like you, to help find the best prostate cancer treatment. This work takes time, effort, resources all of it done by volunteers. Please help us continue. Please Donate!